News
The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.
Humana (HUM) backs reforms on extra Medicare Advantage payments from home visits and chart review. Read more here.
6d
Zacks Investment Research on MSNHumana (HUM) Down 10.1% Since Last Earnings Report: Can It Rebound?A month has gone by since the last earnings report for Humana (HUM). Shares have lost about 10.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...
HealthEquity (HQY) reports strong Q1 2026 growth with increased revenue, reduced fraud costs, and advancements in AI and mobile tech.
Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results